Background: There are limited data evaluating the utilization of dermatologists for the care of patients with hidradenitis suppurativa. Objective: To determine the utilization of the dermatology ambulatory encounter among hidradenitis suppurativa patients, and to evaluate whether utilization varies by insurance status. Methods: This was a retrospective cohort analysis in an adult population sample of 42,030 hidradenitis suppurativa patients with either private or public health insurance who were identified by a validated scheme using SNOMED-CT terminology. The primary outcome was a dichotomous variable defined as having at least 1 ambulatory encounter with a dermatologist over a 3-year period. Results: Overall, 21.8% (9,170/42,020) of the hidradenitis suppurativa patients had at least 1 ambulatory encounter with a dermatologist. This proportion did not significantly vary between patients with private insurance (22%), Medicaid (21.6%), and Medicare (21.7%). Conclusion: Utilization of the ambulatory dermatology encounter among patients with hidradenitis suppurativa is low in the USA. Factors other than insurance status influence this level of utilization.

Jemec GB: Clinical practice: hidradenitis suppurativa. N Engl J Med 2012;366:158-164.
Matusiak L, Bieniek A, Szepietowski JC: Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010;90:264-268.
Esmann S, Jemec GB: Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011;91:328-332.
Deckers IE, Kimball AB: The handicap of hidradenitis suppurativa. Dermatol Clin 2016;34:17-22.
Gooderham M, Papp K: The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol 2015;73:S19-S22.
Garg A, Besen J, Legler A, Lam CS: Factors associated with point-of-care treatment decisions for hidradenitis suppurativa. JAMA Dermatol 2016;152:553-557.
Khalsa A, Liu G, Kirby JS: Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa. J Am Acad Dermatol 2015;73:609-614.
US National Library of Medicine Unified Medical Language System (UMLS): Systematized Nomenclature of Medicine - Clinical Terms (SNOMED CT). (accessed March 29, 2017).
Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R: Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc 2011;18:441-448.
McDonald CJ, Huff SM, Suico JG, Hill G, Aller R, Forrey A, MercerK, DeMoor G, Hook J, Williams W, Case J, Maloney P: LOINC, a universal standard for identifying laboratory observations: a 5-year update. Clin Chem 2003;49:624-633.
Strunk A, Midura M, Papagermanos V, Alloo A, Garg A: Validation of a case finding algorithm for hidradenitis suppurativa using administrative coding from a clinical database. Dermatology 2017;233:53-57.
Garg A, Kirby JS, Lavian J, Lin G, Strunk A: Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol 2017;153:760-764.
Garg A, Lavian J, Lin G, Strunk A, Alloo A: Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol 2017;77:118-122.
Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al: Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 2015;173:1546-1549.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.